-
AI Age Discrepancy: A Novel Parameter for Frailty Assessment in Kidney Tumor Patients
Authors:
Rikhil Seshadri,
Jayant Siva,
Angelica Bartholomew,
Clara Goebel,
Gabriel Wallerstein-King,
Beatriz López Morato,
Nicholas Heller,
Jason Scovell,
Rebecca Campbell,
Andrew Wood,
Michal Ozery-Flato,
Vesna Barros,
Maria Gabrani,
Michal Rosen-Zvi,
Resha Tejpaul,
Vidhyalakshmi Ramesh,
Nikolaos Papanikolopoulos,
Subodh Regmi,
Ryan Ward,
Robert Abouassaly,
Steven C. Campbell,
Erick Remer,
Christopher Weight
Abstract:
Kidney cancer is a global health concern, and accurate assessment of patient frailty is crucial for optimizing surgical outcomes. This paper introduces AI Age Discrepancy, a novel metric derived from machine learning analysis of preoperative abdominal CT scans, as a potential indicator of frailty and postoperative risk in kidney cancer patients. This retrospective study of 599 patients from the 20…
▽ More
Kidney cancer is a global health concern, and accurate assessment of patient frailty is crucial for optimizing surgical outcomes. This paper introduces AI Age Discrepancy, a novel metric derived from machine learning analysis of preoperative abdominal CT scans, as a potential indicator of frailty and postoperative risk in kidney cancer patients. This retrospective study of 599 patients from the 2023 Kidney Tumor Segmentation (KiTS) challenge dataset found that a higher AI Age Discrepancy is significantly associated with longer hospital stays and lower overall survival rates, independent of established factors. This suggests that AI Age Discrepancy may provide valuable insights into patient frailty and could thus inform clinical decision-making in kidney cancer treatment.
△ Less
Submitted 2 July, 2024; v1 submitted 29 June, 2024;
originally announced July 2024.
-
A large dataset curation and benchmark for drug target interaction
Authors:
Alex Golts,
Vadim Ratner,
Yoel Shoshan,
Moshe Raboh,
Sagi Polaczek,
Michal Ozery-Flato,
Daniel Shats,
Liam Hazan,
Sivan Ravid,
Efrat Hexter
Abstract:
Bioactivity data plays a key role in drug discovery and repurposing. The resource-demanding nature of \textit{in vitro} and \textit{in vivo} experiments, as well as the recent advances in data-driven computational biochemistry research, highlight the importance of \textit{in silico} drug target interaction (DTI) prediction approaches. While numerous large public bioactivity data sources exist, res…
▽ More
Bioactivity data plays a key role in drug discovery and repurposing. The resource-demanding nature of \textit{in vitro} and \textit{in vivo} experiments, as well as the recent advances in data-driven computational biochemistry research, highlight the importance of \textit{in silico} drug target interaction (DTI) prediction approaches. While numerous large public bioactivity data sources exist, research in the field could benefit from better standardization of existing data resources. At present, different research works that share similar goals are often difficult to compare properly because of different choices of data sources and train/validation/test split strategies. Additionally, many works are based on small data subsets, leading to results and insights of possible limited validity. In this paper we propose a way to standardize and represent efficiently a very large dataset curated from multiple public sources, split the data into train, validation and test sets based on different meaningful strategies, and provide a concrete evaluation protocol to accomplish a benchmark. We analyze the proposed data curation, prove its usefulness and validate the proposed benchmark through experimental studies based on an existing neural network model.
△ Less
Submitted 30 January, 2024;
originally announced January 2024.
-
Adversarial Balancing for Causal Inference
Authors:
Michal Ozery-Flato,
Pierre Thodoroff,
Matan Ninio,
Michal Rosen-Zvi,
Tal El-Hay
Abstract:
Biases in observational data of treatments pose a major challenge to estimating expected treatment outcomes in different populations. An important technique that accounts for these biases is reweighting samples to minimize the discrepancy between treatment groups. We present a novel reweighting approach that uses bi-level optimization to alternately train a discriminator to minimize classification…
▽ More
Biases in observational data of treatments pose a major challenge to estimating expected treatment outcomes in different populations. An important technique that accounts for these biases is reweighting samples to minimize the discrepancy between treatment groups. We present a novel reweighting approach that uses bi-level optimization to alternately train a discriminator to minimize classification error, and a balancing weights generator that uses exponentiated gradient descent to maximize this error. This approach borrows principles from generative adversarial networks (GANs) to exploit the power of classifiers for measuring two-sample divergence. We provide theoretical results for conditions in which the estimation error is bounded by two factors: (i) the discrepancy measure induced by the discriminator; and (ii) the weights variability. Experimental results on several benchmarks comparing to previous state-of-the-art reweighting methods demonstrate the effectiveness of this approach in estimating causal effects.
△ Less
Submitted 11 September, 2020; v1 submitted 17 October, 2018;
originally announced October 2018.
